George Medicines

George Medicines is a late-stage biopharmaceutical company developing innovative single-pill, fixed-dose combination therapies for cardiometabolic diseases.

Rather than pursuing early drug discovery, the company reformulates established best-in-class small molecules into novel proprietary low-dose combinations designed to improve efficacy, safety, and treatment adherence.

Its lead programme is a triple combination therapy for hypertension that has completed two pivotal Phase III trials with positive data, and is being commercialised across multiple international markets.